Xiidra (Lifitegrast) Patent Expiration, LOE Window & CMS Spending

Xiidra (Lifitegrast) by Bausch Health: FDA Orange Book core substance LOE 2030-10-21 (last listed 2033-12-18), 0 AB generics, $598.3M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN208073 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2030-10-21
Last Listed Patent or Exclusivity Date2033-12-18
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$598.3M
2024 Medicare Part D Spend$505.3M
2024 Medicaid Spend$93.0M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 23.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.